Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

NCT04683198 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Small-cell Lung Cancer

Interventions

DRUG: camrelizumab
DRUG: Apatinib Mesylate
DRUG: Carboplatin
DRUG: Etoposide

Sponsor

Chinese Academy of Medical Sciences